Genetic and epigenetic aspects of bladder cancer

Journal of Cellular Biochemistry

Volumn 95, Issue 1, 2005, Pages 24-33

  Kim, Wun Jae ^a   Quan, Changyi ^a  

^a Chungbuk National University College of Medicine   (South Korea)

Author keywords

Bladder cancer; Genetic alteration; Methylation; Polymorphism

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

ARTICLE; BLADDER; BLADDER CANCER; CANCER DIAGNOSIS; CANCER GENETICS; CANCER RECURRENCE; CARCINOGENESIS; CLINICAL PRACTICE; CYSTOSCOPY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE COURSE; DNA METHYLATION; DNA POLYMORPHISM; EPIGENETICS; GENE MUTATION; HIGH RISK POPULATION; HUMAN; MOLECULAR GENETICS; PARAMETER; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; URINE CYTOLOGY; BLADDER TUMOR; GENETIC EPIGENESIS; GENETICS; PATHOLOGY; REVIEW;

CARCINOMA, TRANSITIONAL CELL; EPIGENESIS, GENETIC; HUMANS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 23844475164     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.20412     Document Type: Article

References (91)

1. Al-Sukhun S, Hussain M. 2003. Molecular biology of transitional cell carcinoma. Crit Rev Oncol Hematol 47:181-193.
2. Baylin SB, Herman JG. 2000. DNA hypermethylation in tumorigenesis: Epigenetics joins genetics. Trends Genet 16:168-174.
3. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, Baylin SB, Herman JG. 1998. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 95:11891-11896.
4. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. 1993. Genetic risk and carcinogen exposure: A common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 85:1159-1164.
5. Berman DM, Wang Y, Liu Z, Dong Q, Burke LA, Liotta LA, Fisher R, Wu X. 2004. A functional polymorphism in RGS6 modulates the risk of bladder cancer. Cancer Res 64:6820-6826.
6. Bornman DM, Mathew S, Alsruhe J, Herman JG, Gabrielson E. 2001. Methylation of the E-cadherin gene in bladder neoplasia and in normal urothelial epithelium from elderly individuals. Am J Pathol 159:831-835.
7. Brockmoller J, Cascorbi I, Kerb R, Roots I. 1996. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 56:3915-3925.
8. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR. 1993. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 143:1255-1262.
9. Bubendorf L. 2001. High-throughput microarray technologies: From genomics to clinics. Eur Urol 40:231-238.
10. Cartwright RA, Glashan RW, Rogers HJ, Ahmad RA, Barham-Hall D, Higgins E, Kahn MA. 1982. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: A pharmacogenetic epidemiological approach to bladder cancer. Lancet 2:842-845.
11. Chan MW, Chan LW, Tang NL, Tong JH, Lo KW, Lee TL, Cheung HY, Wong WS, Chan PS, Lai FM, To KF. 2002. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 8:464-470.
12. Chan MW, Chan LW, Tang NL, Lo KW, Tong JH, Chan AW, Cheung HY, Wong WS, Chan PS, Lai FM, To KF. 2003. Frequent hypermethylation of promoter region of RASSFlA in tumor tissues and voided urine of urinary bladder cancer patients. Int J Cancer 104:611-616.
13. Chang LL, Yeh WT, Yang SY, Wu WJ, Huang CH. 2003. Genetic alterations of p16INK4a and p14ARF genes in human bladder cancer. J Urol 170:595-600.
14. Choi JY, Lee KM, Cho SH, Kim SW, Choi HY, Lee SY, Im HJ, Yoon KJ, Choi H, Choi I, Hirvonen A, Hayes RB, Kang D. 2003. CYP2E1 and NQO1 genotypes, smoking and bladder cancer. Pharmacogenetics 13:349-535.
15. Christensen M, Wolf H, Orntoft TF. 2000. Microsatellite alterations in urinary sediments from patients with cystitis and bladder cancer. Int J Cancer 85:614-617.
16. Cutler SJ, Heney NM, Friedell GH. 1982. Longitudinal study of patients with bladder cancer: Factors associated with disease recurrence and progression. In: Bonney WW, Prout GR, Jr., editors. Bladder cancer. Baltimore, MD: Williams & Wilkins. pp 35-46.
17. Dulaimi E, Uzzo RG, Greenberg RE, Al-Saleem T, Cairns P. 2004. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res 10:1887-1893.
18. Dyrskjot L. 2003. Classification of bladder cancer by microarray expression profiling: Towards a general clinical use of microarrays in cancer diagnostics. Expert Rev Mol Diagn 3:635-647.
19. Dyrskjot L, Thykjaer T, Kruhoffer M, Jensen JL, Marcussen N, Hamilton-Dutoit S, Wolf H, Orntoft TF. 2003. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 33:90-96.
20. Dyrskjot L, Kruhoffer M, Thykjaer T, Marcussen N, Jensen JL, Moller K, Orntoft TF. 2004. Gene expression in the urinary bladder: A common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 64:4040-4048.
21. Espineda C, Seligson DB, James Ball W, Jr., Rao J, Palotie A, Horvath S, Huang Y, Shi T, Rajasekaran AK. 2003. Analysis of the Na, K-ATPase alpha- and beta-subunit expression profiles of bladder cancer using tissue microarrays. Cancer 97:1859-1868.
22. Fadl-Elmula I, Kytola S, Pan Y, Lui WO, Derienzo G, Forsberg L, Mandahl N, Gorunova L, Bergerheim US, Heim S, Larsson C. 2001. Characterization of chromosomal abnormalities in uroepithelial carcinomas by G-banding, spectral karyotyping and FISH analysis. Int J Cancer 92:824-831.
23. Falor WH, Ward-Skinner RM. 1988. The importance of marker chromosomes in superficial transitional cell carcinoma of the bladder: 50 patients followed up to 17 years. J Urol 139:929-932.
24. Grant DM, Tang BK, Kalow W. 1983. Polymorphic N-acetylation of a caffeine metabolite. Clin Pharmacol Ther 33:355-359.
25. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. 2001. Cancer statistics, 2001. CA Cancer J Clin 51:15-36.
26. Habdous M, Siest G, Herbeth B, Vincent-Viry M, Visvikis S. 2004. Glutathione S-transferases genetic polymorphisms and human diseases: Overview of epidemiological studies. Ann Biol Clin (Paris) 62:15-24.
27. Habuchi T, Takahashi T, Kakinuma H, Wang L, Tsuchiya N, Satoh S, Akao T, Sato K, Ogawa O, Knowles MA, Kato T. 2001. Hypermethylation at 9q32-33 tumour suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer. Oncogene 20:531-537.
28. Hein DW. 1988. Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta 948:37-66.
29. Horikawa Y, Sugano K, Shigyo M, Yamamoto H, Nakazono M, Fujimoto H, Kanai Y, Hirohashi S, Kakizoe T, Habuchi T, Kato T. 2003. Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ. J Urol 169:1541-1545.
30. Ichimura Y, Habuchi T, Tsuchiya N, Wang L, Oyama C, Sato K, Nishiyama H, Ogawa O, Kato T. 2004. Increased risk of bladder cancer associated with a glutathione peroxidase 1 codon 198 variant. J Urol 172:728-732.
31. Jeong HJ, Kim HJ, Seo IY, Kim HJ, Oh GJ, Chae SC, Lim JS, Chung HT, Kim JJ. 2003. Association between glutathione S-transferase M1 and T1 polymorphisms and increased risk for bladder cancer in Korean smokers. Cancer Lett 202:193-199.
32. Jeong P, Kim EJ, Kim EG, Byun SS, Kim CS, Kim WJ. 2004. Association of bladder tumors and GA genotype of-308 nucleotide in tumor necrosis factor-alpha promoter with greater tumor necrosis factor-alpha expression. Urology 64:1052-1056.
33. Jones PA, Laird PW. 1999. Cancer epigenetics comes of age. Nat Genet 21:163-167.
34. Katoh T, Inatomi H, Kim H, Yang M, Matsumoto T, Kawamoto T. 1998. Effects of glutathione S-transferase (GST) M1 and GSTT1 genotypes on urothelial cancer risk. Cancer Lett 132:147-152.
35. Kelsey KT, Park S, Nelson HH, Karagas MR. 2004. A population-based case-control study of the XRCC1 Arg399Gln polymorphism and susceptibility to bladder cancer. Cancer Epidemiol Biomarkers Prev 13:1337-1341.
36. Kempkes M, Golka K, Reich S, Reckwitz T, Bolt HM. 1996. Glutathione S-transferase GSTM1 and GSTT1 null genotypes as potential risk factors for urothelial cancer of the bladder. Arch Toxicol 71:123-126.
37. Kim WJ, Lee HL, Lee SC, Kim YT, Kim H. 2000. Polymorphisms of N-acetyltransferase 2, glutathione S-transferase mu and theta genes as risk factors of bladder cancer in relation to asthma and tuberculosis. J Urol 164:209-213.
38. Kim WJ, Kim H, Kim CH, Lee MS, Oh BR, Lee HM, Katoh T. 2002. GSTT1-null genotype is a protective factor against bladder cancer. Urology 60:913-918.
39. Kim EJ, Jeong P, Quan C, Kim J, Bae SC, Yoon SJ, Kang JW, Lee SC, Wee JJ, Kim WJ. 2005. Genotypes of TNF-α, VEGF, hOGG1, GSTM1 and GSTT1: Useful determinants for the Clinical Outcome of Bladder Cancer. Urology 68:70-75.
40. Klungland A, Rosewell I, Hollenbach S, Larsen E, Daly G, Epe B, Seeberg E, Lindahl T, Barnes DE. 1999. Accumulation of premutagenic DNA lesions in mice defective in removal of oxidative base damage. Proc Natl Acad Sci USA 96:13300-13305.
41. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. 1998. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844-847.
42. Koss LG. 1979. Mapping of the urinary bladder: Its impact on the concepts of bladder cancer. Hum Pathol 10:533-548.
43. Larsson PC, Beheshti B, Sampson HA, Jewett MA, Shipman R. 2001. Allelic deletion fingerprinting of urine cell sediments in bladder cancer. Mol Diagn 6:181-188.
44. Lee YS, Lee HS, Park MK, Hwang ES, Park EM, Kasai H, Chung MH. 1993. Identification of 8-hydroxyguanine glycosylase activity in mammalian tissues using 8-hydroxyguanine specific monoclonal antibody. Biochem Biophys Res Commun 196:1545-1551.
45. Lee MG, Kim HY, Byun DS, Lee SJ, Lee CH, Kim JI, Chang SG, Chi SG. 2001. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Res 61: 6688-6692.
46. Lothe RA, Peltomaki P, Meling GI, Aaltonen LA, Nystrom-Lahti M, Pylkkanen L, Heimdal K, Andersen TI, Moller P, Rognum TO, Fossa SD, Haldorsen T, Langmark F, Brogger A, de la Chapelle A, Borresen AL. 1993. Genomic instability in colorectal cancer: Relationship to clinicopathological variables and family history. Cancer Res 53: 5849-5852.
47. Maruyama R, Toyooka S, Toyooka KO, Harada K, Virmani AK, Zochbauer-Muller S, Farinas AJ, Vakar-Lopez F, Minna JD, Sagalowsky A, Czerniak B, Gazdar AF. 2001. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 61:8659-8663.
48. Messing EM. 2002. Urothelial tumors of the urinary tract. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, editor. Campbell's urology 8th edn. Pennsylvania: Saunders. pp 2750-2751.
49. Morrison AS, Buring JE, Verhoek WG, Aoki K, Leek I, Ohno Y, Obata K. 1984. An international study of smoking and bladder cancer. J Urol 131:650-654.
50. Nebert DW. 1994. Drug-metabolizing enzymes in ligand-modulated transcription. Biochem Pharmacol 47:25-37.
51. Nocito A, Bubendorf L, Maria Tinner E, Suess K, Wagner U, Forster T, Kononen J, Fijan A, Bruderer J, Schmid U, Ackermann D, Maurer R, Alund G, Knonagel H, Rist M, Anabitarte M, Hering F, Hardmeier T, Schoenenberger AJ, Flury R, Jager P, Luc Fehr J, Schraml P, Moch H, Mihatsch MJ, Gasser T, Sauter G. 2001. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 194:349-357.
52. Nuovo GJ, Plaia TW, Belinsky SA, Baylin SB, Herman JG. 1999. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc Natl Acad Sci USA 96:12754-12759.
53. Olumi AF, Tsai YC, Nichols PW, Skinner DG, Cain DR, Bender LI, Jones PA. 1990. Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res 50:7081-7083.
54. Orlow I, LaRue H, Osman I, Lacombe L, Moore L, Rabbani F, Meyer F, Fradet Y, Cordon-Cardo C. 1999. Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. Am J Pathol 155:105-113.
55. Peltomaki P, de la Chapelle A. 1997. Mutations predisposing to hereditary nonpolyposis colorectal cancer. Adv Cancer Res 71:93-119.
56. Pemble S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E, Bolt HM, Ketterer B, Taylor JB. 1994. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 300:271-276.
57. Ponder BA. 2001. Cancer genetics. Nature 411:336-341.
58. Presti JC, Jr., Reuter VE, Galan T, Fair WR, Cordon-Cardo C. 1991. Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res 51: 5405-5409.
59. Rao J, Seligson D, Visapaa H, Horvath S, Eeva M, Michel K, Pantuck A, Belldegrun A, Palotie A. 2002. Tissue microarray analysis of cytoskeletal actin-associated biomarkers gelsolin and E-cadherin in urothelial carcinoma. Cancer 95:1247-1257.
60. Razin A, Riggs AD. 1980. DNA methylation and gene function. Science 210:604-610.
61. Ribeiro-Filho LA, Franks J, Sasaki M, Shiina H, Li LC, Nojima D, Arap S, Carroll P, Enokida H, Nakagawa M, Yonezawa S, Dahiya R. 2002. CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer. Mol Carcinog 34:187-198.
62. Richter J, Wagner U, Kononen J, Fijan A, Bruderer J, Schmid U, Ackermann D, Maurer R, Alund G, Knonagel H, Rist M, Wilber K, Anabitarte M, Hering F, Hardmeier T, Schonenberger A, Flury R, Jager P, Fehr JL, Schraml P, Moch H, Mihatsch MJ, Gasser T, Kallioniemi OP, Sauter G. 2000. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol 157:787-794.
63. Robertson KD. 2001. DNA methylation, methyltransferases, and cancer. Oncogene 20:3139-3155.
64. Salem C, Liang G, Tsai YC, Coulter J, Knowles MA, Feng AC, Groshen S, Nichols PW, Jones PA. 2000. Progressive increases in de novo methylation of CpG islands in bladder cancer. Cancer Res 60:2473-2476.
65. Sanchez-Carbayo M, Socci ND, Lozano JJ, Li W, Charytonowicz E, Belbin TJ, Prystowsky MB, Ortiz AR, Childs G, Cordon-Cardo C. 2003. Gene discovery in bladder cancer progression using cDNA microarrays. Am J Pathol 163:505-516.
66. Sandberg AA, Berger CS. 1994. Review of chromosome studies in urological tumors. II. Cytogenetics and molecular genetics of bladder cancer. J Urol 151:545-560.
67. Sandberg AA, Berger CS, Haddad FS, Kerr D, Hecht F. 1986. Chromosome change in transitional cell carcinoma of ureter. Cancer Genet Cytogenet 19:335-340.
68. Sardi I, Bartoletti R, Occhini I, Piazzini M, Travaglini F, Guazzelli R, Montali E. 1999. Microsatellite alterations in superficial and locally advanced transitional cell carcinoma of the bladder. Oncol Rep 6:901-905.
69. Sasaki M, Nakajima K, Perinchery G, Fujino T, Oh BR, Fujimoto S, Dahiya R. 2000. Frequent genotype changes at -308 of the human tumor necrosis factor-alpha promoter region in human uterine endometrial cancer. Oncol Rep 7:369-373.
70. Sathyanarayana UG, Maruyama R, Padar A, Suzuki M, Bondaruk J, Sagalowsky A, Minna JD, Frenkel EP, Grossman HB, Czerniak B, Gazdar AF. 2004. Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes. Cancer Res 64:1425-1430.
71. Schraml P, Kononen J, Bubendorf L, Moch H, Bissig H, Nocito A, Mihatsch MJ, Kallioniemi OP, Sauter G. 1999. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 5:1966-1975.
72. Seidegard J, Pero RW, Miller DG, Beattie EJ. 1986. A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer. Carcinogenesis 7: 751-753.
73. Seripa D, Parrella P, Gallucci M, Gravina C, Papa S, Fortunato P, Alcini A, Flammia G, Lazzari M, Fazio VM. 2001. Sensitive detection of transitional cell carcinoma of the bladder by microsatellite analysis of cells exfoliated in urine. Int J Cancer 95:364-369.
74. Shen M, Hung RJ, Brennan P, Malaveille C, Donate F, Placidi D, Carta A, Hautefeuille A, Boffetta P, Porru S. 2003. Polymorphisms of the DNA repair genes XRCC1, XRCC3, XPD, interaction with environmental exposures, and bladder cancer risk in a case-control study in northern Italy. Cancer Epidemiol Biomarkers Prev 12: 1234-1240.
75. Sinues B, Perez J, Bernal ML, Saenz MA, Lanuza J, Bartolome M. 1992. Urinary mutagenicity and N-acetylation phenotype in textile industry workers exposed to arylamines. Cancer Res 52:4885-4889.
76. Soulitzis N, Sourvinos G, Dokianakis DN, Spandidos DA. 2002. p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett 179:175-183.
77. Stern MC, Johnson LR, Bell DA, Taylor JA. 2002a. XPD codon 751 polymorphism, metabolism genes, smoking, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 11:1004-1011.
78. Stern MC, Umbach DM, Lunn RM, Taylor JA. 2002b. DNA repair gene XRCC3 codon 241 polymorphism, its interaction with smoking and XRCC1 polymorphisms, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 11:939-943.
79. Tada Y, Wada M, Taguchi K, Mochida Y, Kinugawa N, Tsuneyoshi M, Naito S, Kuwano M. 2002. The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res 62:4048-4053.
80. Tchou J, Kasai H, Shibutani S, Chung MH, Laval J, Grollman AP, Nishimura S. 1991. 8-oxoguanine (8-hydroxyguanine) DNA glycosylase and its substrate specificity. Proc Natl Acad Sci USA 88:4690-4694.
81. Thibodeau SN, Bren G, Schaid D. 1993. Microsatellite instability in cancer of the proximal colon. Science 260:816-819.
82. Thykjaer T, Christensen M, Clark AB, Hansen LR, Kunkel TA, Orntoft TF. 2001. Functional analysis of the mismatch repair system in bladder cancer. Br J Cancer 85: 568-575.
83. Toruner GA, Akyerli C, Ucar A, Aki T, Atsu N, Ozen H, Tez M, Cetinkaya M, Ozcelik T. 2001. Polymorphisms of glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and bladder cancer susceptibility in the Turkish population. Arch Toxicol 75:459-464.
84. Tsai YC, Nichols PW, Hiti AL, Williams Z, Skinner DG, Jones PA. 1990. Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. Cancer Res 50:44-47.
85. Uchida T, Wang C, Wada C, Iwamura M, Egawa S, Koshiba K. 1996. Microsatellite instability in transitional cell carcinoma of the urinary tract and its relationship to clinicopathological variables and smoking. Int J Cancer 69:142-145.
86. Valenzuela MT, Galisteo R, Zuluaga A, Villalobos M, Nunez MI, Oliver FJ, Ruiz de Almodovar JM. 2002. Assessing the use of p 16 (INK4a) promoter gene methylation in serum for detection of bladder cancer. Eur Urol 42:622-630.
87. Wang L, Habuchi T, Takahashi T, Mitsumori K, Kamoto T, Kakehi Y, Kakinuma H, Sato K, Nakamura A, Ogawa O, Kato T. 2002. Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis 23:257-264.
88. Warzocha K, Ribeiro P, Bienvenu J, Roy P, Chariot C, Rigal D, Coiffier B, Salles G. 1998. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood 91:3574-3581.
89. Wong IH, Lo YM, Zhang J, Liew CT, Ng MH, Wong N, Lai PB, Lau WY, Hjelm NM, Johnson PJ. 1999. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res 59:71-73.
90. Yu MC, Skipper PL, Taghizadeh K, Tannenbaum SR, Chan KK, Henderson BE, Ross RK. 1994. Acetylator phenotype, aminobiphenyl-hemoglobin adduct levels, and bladder cancer risk in white, black, and Asian men in Los Angeles, California. J Natl Cancer Inst 86:712-716.
91. Zhang X, Ma X, Zhu QG, Li LC, Chen Z, Ye ZQ. 2003. Association between a C/A single nucleotide polymorphism of the E-cadherin gene promoter and transitional cell carcinoma of the bladder. J Urol 170:1379-1382.